Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/09/12 → 1/06/13 |
A phase 3 randomised open-labeled study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable or m
- Parente, Phillip (Primary Chief Investigator (PCI))
Project: Research